STOCK TITAN

Oncolytics Biotech Inc - ONCY STOCK NEWS

Welcome to our dedicated page for Oncolytics Biotech news (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech stock.

Oncolytics Biotech Inc (ONCY) is a clinical-stage biotech company advancing pelareorep, an innovative oncolytic virus immunotherapy targeting multiple cancer types. This dedicated news hub provides investors and researchers with centralized access to corporate developments and scientific progress updates.

Track critical updates including clinical trial results, regulatory milestones, and strategic partnerships. Our curated collection features press releases spanning Phase 2 breast cancer studies, pancreatic cancer research advancements, and manufacturing capacity expansions. Regular updates ensure timely awareness of key developments in HR+/HER2- metastatic breast cancer trials and other high-priority programs.

Discover verified information on pelareorep's mechanism of action, trial design specifics, and intellectual property developments. The resource eliminates the need by aggregating essential updates from randomized controlled studies to manufacturing quality initiatives. Bookmark this page for efficient monitoring of Oncolytics' progress in transforming cancer treatment through viral immunotherapy approaches.

Rhea-AI Summary
Oncolytics Biotech announces positive results from the Phase 1/2 GOBLET study evaluating pelareorep-based combination therapy in patients with pancreatic ductal adenocarcinoma (PDAC) at ESMO 2023. The study shows an overall response rate of 62%, median progression-free survival of 7.2 months, and interim median overall survival of 10.6 months. T-cell expansion data correlate with tumor response. The treatment combination has been well tolerated with no safety concerns.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.03%
Tags
-
Rhea-AI Summary
Oncolytics Biotech announces positive interim results from the Phase 1/2 GOBLET study evaluating pelareorep in patients with third-line metastatic colorectal cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.03%
Tags
none
-
Rhea-AI Summary
Oncolytics Biotech to host conference call and webcast on November 3, 2023, to discuss corporate update and financial results for Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.32%
Tags
conferences earnings
Rhea-AI Summary
Oncolytics Biotech announces the publication of two abstracts for posters to be presented at the ESMO Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
conferences
-
Rhea-AI Summary
Oncolytics Biotech receives $5 million grant from PanCAN for pancreatic cancer research
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.69%
Tags
none
-
Rhea-AI Summary
Oncolytics Biotech® Inc. to participate in fireside chat at Cantor Global Healthcare Conference 2023 with CEO Dr. Matt Coffey. One-on-one investor meetings available. Webcast link provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.45%
Tags
none
Rhea-AI Summary
Oncolytics Biotech CEO to participate in fireside chat at H.C. Wainwright conference on Sep 12, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
conferences
-
Rhea-AI Summary
Oncolytics Biotech announces positive results from Phase 2 trial in breast cancer and inclusion in Precision Promise trial for pancreatic cancer. Financials show $24.4 million in cash and a successful $15 million public offering. Management to host conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
conferences earnings
Oncolytics Biotech Inc

Nasdaq:ONCY

ONCY Rankings

ONCY Stock Data

48.58M
82.87M
4.35%
1.62%
3.44%
Biotechnology
Healthcare
Link
Canada
Calgary